Why the study?
What are the rates of fatal recurrent PE and fatal bleeding in cancer patients receiving anticoagulant therapy for VTE?
Population
7,911 patients with active cancer and venous thromboembolism from the RIETE Registry
Design
Cohort
Follow-up
mean 181 ± 210 days
Authors
Loading...
May support closer early monitoring in cancer VTE; leaves optimal duration open for trials.
What are the rates of fatal recurrent PE and fatal bleeding in cancer patients receiving anticoagulant therapy for VTE?
In cancer patients with VTE, the risk of fatal recurrent PE and fatal bleeding is highest during the first 3 months of anticoagulant therapy.
Farge et al. (2015) studied this question.